NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Forecast, Price & News

$5.48

-0.06 (-1.08%)

(As of 09/27/2023 ET)

Compare

Today's Range: $5.14
▼
$5.55
50-Day Range: $5.54
▼
$9.19
52-Week Range: $5.14
▼
$60.00

Volume: 3,853 shs
Average Volume: 17,406 shs
Market Capitalization: $8.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $210.00

Finch Therapeutics Group MarketRank™ Forecast

Analyst Rating: 0.00 Rating Score
Upside/Downside: 3,732.1% Upside
$210.00 Price Target
Short Interest: Bearish
5.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($30.98) to ($20.59) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $210.00, Finch Therapeutics Group has a forecasted upside of 3,732.1% from its current price of $5.48.
Amount of Analyst Coverage
Finch Therapeutics Group has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.05% of the float of Finch Therapeutics Group has been sold short.
Short Interest Ratio / Days to Cover
Finch Therapeutics Group has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Finch Therapeutics Group has recently increased by 27.23%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Finch Therapeutics Group does not currently pay a dividend.
Dividend Growth
Finch Therapeutics Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FNCH.

1.9

News and Social Media Coverage

News Sentiment
Finch Therapeutics Group has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Finch Therapeutics Group this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for FNCH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Finch Therapeutics Group insiders have not sold or bought any company stock.
Percentage Held by Insiders
44.90% of the stock of Finch Therapeutics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 15.43% of the stock of Finch Therapeutics Group is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Finch Therapeutics Group are expected to grow in the coming year, from ($30.98) to ($20.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Finch Therapeutics Group is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Finch Therapeutics Group is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Finch Therapeutics Group has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Finch Therapeutics Group (NASDAQ:FNCH) Stock

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

FNCH Price History

30 days | 90 days | 365 days | Advanced Chart

FNCH Stock News Headlines

September 19, 2023 | americanbankingnews.com

Finch Therapeutics Group (NASDAQ:FNCH) Stock Price Down 2.6%

August 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

June 9, 2023 | finanznachrichten.de

Finch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common Stock

May 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Finch Therapeutics Group (FNCH) Buy Recommendation

May 12, 2023 | marketwatch.com

8-K: Finch Therapeutics Group, Inc.

May 10, 2023 | finanznachrichten.de

Finch Therapeutics Group, Inc.: Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 10, 2023 | finance.yahoo.com

Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

April 25, 2023 | finance.yahoo.com

Finch Therapeutics Announces Executive Leadership Transitions

April 22, 2023 | finanznachrichten.de

FINCH THERAPEUTICS GROUP INC

April 18, 2023 | finance.yahoo.com

Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement

April 4, 2023 | markets.businessinsider.com

Finch Therapeutics Group (FNCH) Gets a Buy from H.C. Wainwright

April 3, 2023 | finanznachrichten.de

Finch Therapeutics Group, Inc.: Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 25, 2023 | msn.com

Looking Into Finch Therapeutics Group's Return On Capital Employed

March 25, 2023 | finance.yahoo.com

Finch Therapeutics Group Full Year 2022 Earnings: Misses Expectations

March 23, 2023 | finance.yahoo.com

Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

January 24, 2023 | finance.yahoo.com

Microbiome startup cuts 95% of remaining staff in 3rd layoff in 9 months

January 24, 2023 | marketwatch.com

Finch Therapeutics Ending Phase 3 Study, Cutting Most of Workforce >FNCH

January 24, 2023 | finance.yahoo.com

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

November 11, 2022 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Kezar Life Sciences (KZR), RVL Pharmaceuticals (RVLP)

November 11, 2022 | finance.yahoo.com

Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

November 9, 2022 | finance.yahoo.com

Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

October 24, 2022 | finance.yahoo.com

Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection

October 1, 2022 | seekingalpha.com

FNCH Finch Therapeutics Group, Inc.

September 1, 2022 | finance.yahoo.com

After Takeda ends collaboration, microbiome startup Finch Therapeutics cuts 50 jobs

September 1, 2022 | markets.businessinsider.com

Finch Therapeutics To Reduce Workforce - Quick Facts

See More Headlines

Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

FNCH Company Calendar

Last Earnings: 8/10/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:FNCH
CUSIP: N/A
CIK: 1733257
Web: www.finchtherapeutics.com
Phone: 617-229-6499
Fax: N/A
Employees: 18
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $210.00
High Stock Price Forecast: $210.00
Low Stock Price Forecast: $210.00
Forecasted Upside/Downside: +3,732.1%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($86.6130)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-114,650,000.00
Net Margins: -25,084.36%
Pretax Margin: -56,019.37%
Return on Equity: -115.37%
Return on Assets: -64.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.81
Quick Ratio: 3.81

Sales & Book Value

Annual Sales: $860,000.00
Price / Sales: 10.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $60.01 per share
Price / Book: 0.09

Miscellaneous

Outstanding Shares: 1,600,000
Free Float: 884,000
Market Cap: $8.77 million
Optionable: Not Optionable
Beta: 0.17

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Matthew P. Blischak J.D.
Chief Exec. Officer

Mr. Lance Thibault CPA (Age 57)
CPA, Chief Financial Officer

Mr. James S. Sigler MBA (Age 62)
Exec. VP of CMC

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FNCH Stock - Frequently Asked Questions

What is Finch Therapeutics Group's stock price forecast for 2023?: 0 Wall Street research analysts have issued 12 month target prices for Finch Therapeutics Group's stock. Their FNCH share price forecasts range from $210.00 to $210.00. On average, they predict the company's share price to reach $210.00 in the next twelve months. This suggests a possible upside of 3,732.1% from the stock's current price.
View analysts price targets for FNCH or view top-rated stocks among Wall Street analysts.
How have FNCH shares performed in 2023?: Finch Therapeutics Group's stock was trading at $14.40 at the start of the year. Since then, FNCH shares have decreased by 61.9% and is now trading at $5.48.
View the best growth stocks for 2023 here.
Are investors shorting Finch Therapeutics Group?: Finch Therapeutics Group saw a increase in short interest in September. As of September 15th, there was short interest totaling 28,500 shares, an increase of 27.2% from the August 31st total of 22,400 shares. Based on an average daily trading volume, of 10,500 shares, the days-to-cover ratio is presently 2.7 days. Currently, 5.1% of the company's shares are short sold.
View Finch Therapeutics Group's Short Interest.
When is Finch Therapeutics Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our FNCH earnings forecast.
How were Finch Therapeutics Group's earnings last quarter?: Finch Therapeutics Group, Inc. (NASDAQ:FNCH) posted its earnings results on Thursday, August, 10th. The company reported ($4.33) earnings per share for the quarter, beating analysts' consensus estimates of ($4.51) by $0.18. Finch Therapeutics Group had a negative net margin of 25,084.36% and a negative trailing twelve-month return on equity of 115.37%.
When did Finch Therapeutics Group's stock split?: Finch Therapeutics Group shares reverse split before market open on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Finch Therapeutics Group IPO?: (FNCH) raised $101 million in an IPO on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO.
What is Finch Therapeutics Group's stock symbol?: Finch Therapeutics Group trades on the NASDAQ under the ticker symbol "FNCH."
Who are Finch Therapeutics Group's major shareholders?: Finch Therapeutics Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Baupost Group LLC MA (4.21%) and Lake Street Advisors Group LLC (1.32%). Insiders that own company stock include Jeffery A Smisek, Marc Blaustein and Nicholas Haft.
View institutional ownership trends.
How do I buy shares of Finch Therapeutics Group?: Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Finch Therapeutics Group's stock price today?: One share of FNCH stock can currently be purchased for approximately $5.48.
How much money does Finch Therapeutics Group make?: Finch Therapeutics Group (NASDAQ:FNCH) has a market capitalization of $8.77 million and generates $860,000.00 in revenue each year. The company earns $-114,650,000.00 in net income (profit) each year or ($86.6130) on an earnings per share basis.
How can I contact Finch Therapeutics Group?: The official website for the company is www.finchtherapeutics.com. The company can be reached via phone at 617-229-6499 or via email at ir@finchtherapeutics.com.

This page (NASDAQ:FNCH) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial